Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 program

SAN FRANCISCO, CA, USA I November 10, 2022 I Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 8 – 12th in Boston. Nurix also announced the successful completion of the safety run-in portion of the ongoing Phase 1 trial of DeTIL-0255 in patients with advanced gynecologic malignancies and revealed that it has received feedback from the FDA regarding the potential combination of DeTIL-0255 with the oral CBL-B inhibitor NX-1607. The FDA feedback, the preliminary safety profile of DeTIL-0255, and the potential benefits of combining DeTIL-0255 with in vivo pharmacologic inhibition of CBL-B with NX-1607 provide a path for a potential future combination trial to explore whether inhibiting CBL-B both ex vivo and in vivo may enhance the anti-tumor potential of adoptive cell therapy.

“We believe that our portfolio of first-in-class CBL-B inhibitors has the potential to improve outcomes for patients with solid tumors and enhance the field of cell therapy,” said Robert J. Brown, M.D., executive vice president of clinical development at Nurix. “Pending successful completion of Nurix’s NX-1607 Phase 1a dose escalation trial, we envision expanding the use of NX-1607 as a single agent in selected indications in 2023. We also can see a path to exploring the potential for a combination strategy with DeTIL-0255 in accordance with recent feedback from the FDA.”

The Phase 1 safety run-in includes three patients with advanced epithelial ovarian cancer (EOC) who have been dosed with DeTIL-0255 and have cleared the initial safety evaluation. Expansion of the Phase 1 trial will be postponed, pending potential inclusion of NX-1607 in future cohorts.

Summary of DeTIL-0255-related data presented at the SITC meeting:

Title: A novel small molecule inhibitor of CBL-B shows potent antitumor activity in combination with Pmel-1 adoptive cell transfer in an aggressive mouse melanoma model
Current adoptive cell transfer (ACT) treatment paradigms require application of high dose bolus infusions of IL-2 which are associated with acute toxicities, restricting the use of ACT in the clinic. The results presented in this poster demonstrate that production of ACT supported by ex vivo use of NX-0255 combined with in vivo oral treatment with NX-1607:

  • Increases the antitumor activity of the transferred T cells when compared to ACT alone and
  • Induces a more favorable anti-tumor activity phenotype of the adoptively transferred T cells compared to treatment with IL-2

These observed anti-tumor effects of NX-1607 support its potential use in combination with cell-based therapeutics.

Title: The CBL-B inhibitor, NX-0255, improves human drug enhanced tumor infiltrating lymphocyte (DeTIL-0255) expansion and T-cell function in full-scale runs
These studies demonstrate that addition of NX-0255, a highly potent CBL-B inhibitor, during ex-vivo TIL expansion results in a favorable TIL phenotype and higher cell yields at research scale. Data from six full-scale manufacturing runs of different tumor types are presented demonstrating that addition of NX-0255 in the cell expansion phase significantly increases the total number of CD8+ T cells with a central memory and ‘stem-like’ memory phenotype. In addition, the expression profile of genes associated with tumor killing activities was enhanced in NX-0255 treated cells when compared with conventional TIL.

Title: Universal expansion of CBL-B-inhibited tumor infiltrating lymphocytes, DeTIL-0255, from women with ovarian cancer: process validation 
In this poster, data are presented from both research and clinical scale manufacturing studies demonstrating that Nurix has developed a process in which cells are exposed to NX-0255 during the cell expansion phase of manufacturing that yields a superior TIL product for patients with ovarian cancer with a favorable phenotype amenable for adoptive cell therapy.

About DeTIL-0255
DeTIL-0255 is an autologous cell therapy consisting of T cells derived from a patient’s tumor expanded in culture with recombinant interleukin-2 and the small molecule CBL-B inhibitor NX-0255. DeTIL-0255 is designed to be a single administration autologous TIL therapy infused following non-myeloablative chemotherapy. DeTIL-0255 is currently being evaluated in a Phase 1 clinical trial in patients with advanced gynecologic tumors. Additional information on the ongoing clinical trial can be accessed at (NCT05107739).

About NX-1607
NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. Nurix is evaluating NX-1607 in an ongoing, Phase 1 dose escalation and expansion trial in adults with a variety of oncology indications at multiple clinical sites. Additional information on the clinical trial can be accessed at (NCT05107674).

About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit

SOURCE: Nuruix

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up